Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex

Advanced MRSA Test Receives US FDA Approval

By Labmedica International staff writers
Posted on 30 Jan 2014
Image: The fully automated BD MAX System (Photo courtesy of Becton, Dickinson and Company).
Image: The fully automated BD MAX System (Photo courtesy of Becton, Dickinson and Company).
Clinical laboratories in the United States can now take advantage of a dedicated assay for the rapid diagnosis of MRSA (methicillin-resistant Staphylococus aureus) infections.

The global medical and biotechnological company Becton, Dickinson and Company (Franklin Lakes, NJ, USA) announced that the MAX MRSA XT Assay, which is marketed by their BD Diagnosis subsidiary, had received [US] Food and Drug Administration (FDA) 510(k) approval for use as a diagnostic test.

The MAX MRSA XT Assay is intended for use on the fully automated BD MAX System and complements the MAX StaphSR Assay, which reports results for both Staphylococus aureus (SA) and MRSA.

Both assays employ BD's eXTended Detection Technology to identify a broad range of SA strains including mecA and mecC dropout mutants and new strains of MRSA that may not be detected by other assays.

"Assay design is critical to detect MRSA accurately and ensure appropriate infection control interventions are applied," said Dr. Patrick Murray, worldwide director of scientific affairs at BD Diagnostics. "The BD MAX MRSA XT Assay helps improve patient safety by providing hospitals with a new solution to detect the latest strains of this drug-resistant superbug."

Related Links:

Becton, Dickinson and Company



Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more


view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more


view channel
Image: Immunostaining of human lung tissue, fixed with HOPE, from a patients suffering from legionnaire\'s disease. One legionella protein (red-brown), the bacteria-containing vacuoles and individual legionella inside the scavenger cells can be detected. The infection process can be observed immediately using proteomics (Photo courtesy of Braunschweig University of Technology).

Novel Method Prepares Tissue Samples for Analyzing Proteins

A new way of preparing patient tissue for analyses might soon become the new standard, possibly replacing tissues fixed with formalin, before they are embedded in wax-like paraffin and cut into razor-thin slices.... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
Copyright © 2000-2014 Globetech Media. All rights reserved.